HealthEquity stock adds a director after Q2 revenue reaches USD 350.73 million

Published on 10/04/2026 at 21:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

HealthEquity stock stood at USD 90.04 on October 2, with a 52-week range of USD 72.76 to USD 107.62. Q2 fiscal 2027 revenue reached USD 350.73 million.

HQY, US42226A1079, Illustration mit AI erstellt.

HealthEquity (ISIN US42226A1079) was last at USD 90.04 on Nasdaq on October 2, 2026, up 0.75 percent from the prior close. The company appointed Moody's Chief Financial Officer Noémie Heuland to its board effective September 24, 2026, adding a finance and technology executive as HealthEquity scales its healthcare savings platform.

Board gains a finance specialist

According to GlobeNewswire on September 30, 2026, Heuland will serve on HealthEquity's Audit and Risk Committee and Cybersecurity and Technology Committee.

The appointment expands the board to 11 directors, including nine independent members. That governance change adds directly relevant finance and technology experience while the company manages sensitive healthcare and custodial account data.

Q2 revenue climbs 7.6 percent

HealthEquity reported USD 350.73 million in revenue for second-quarter fiscal 2027, up 7.6 percent year over year, according to TradingView on September 4, 2026.

Adjusted EPS reached USD 1.24, up 14.8 percent year over year, while adjusted EBITDA margin reached 48 percent. The same report said HealthEquity raised fiscal 2027 revenue guidance to USD 1.411 billion to USD 1.421 billion and reaffirmed adjusted EPS guidance of USD 4.66 to USD 4.73.

Finance data for the quarter ended July 31, 2026, show GAAP net income of USD 65.644 million and diluted EPS of USD 0.78. Operating cash flow was USD 136.159 million for that quarter, giving the earnings story a cash-generation counterpoint.

Consensus target sits above price

MarketBeat's October 4, 2026 consensus covers 13 analysts and carries a Moderate Buy rating. The average target is USD 112.20, with a high of USD 142.00 and a low of USD 89.00, according to MarketBeat.

The average target lies 24.61 percent above the USD 90.04 price. The range also shows a divided valuation picture: the low target is below the latest price, while the high target is USD 51.96 higher.

A separate risk factor is cybersecurity. HealthEquity handles personal healthcare information and custodial balances, and the company faces litigation and regulatory inquiries connected to a fiscal 2025 cybersecurity incident, as reported by TradingView.

Stock remains below yearly high

HealthEquity stock was last at USD 90.04 on Nasdaq on October 2, 2026, with a session range of USD 88.70 to USD 91.02. Its 52-week range was USD 72.76 to USD 107.62, placing the latest price 16.34 percent below the yearly high.